Stoke Therapeutics (STOK) Free Cash Flow (2018 - 2026)
Stoke Therapeutics (STOK) posted quarterly Free Cash Flow of -$60.9 million for Q1 2026, down 146.23% year-over-year from $131.8 million in Q1 2025, and down 96.36% quarter-over-quarter from -$31.0 million in Q4 2025.
Powered by 
Analysis
Stoke Therapeutics (STOK) Free Cash Flow (2018 - 2026) Analysis & Trends
Stoke Therapeutics' Free Cash Flow history runs 9 years deep, the most recent figure standing at -$60.9 million for Q1 2026.
- In Q1 2026, Free Cash Flow fell 146.23% year-over-year to -$60.9 million; the TTM figure through Mar 2026 stood at -$147.8 million (down 313.25% YoY), while the FY2025 annual figure was $44.9 million, up 151.59% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$60.9 million, down from -$31.0 million in the prior quarter.
- The five-year high for Free Cash Flow was $131.8 million in Q1 2025, with the low at -$60.9 million in Q1 2026.
- The 5-year median for Free Cash Flow is -$21.7 million (2022), against an average of -$12.8 million.
- The sharpest annual moves came in 2023 and 2025: Free Cash Flow tumbled 168.0% in 2023, then soared 636.38% in 2025.
- Stoke Therapeutics' Free Cash Flow stood at -$22.1 million in 2022, then increased by 5.48% to -$20.9 million in 2023, then declined by 12.01% to -$23.4 million in 2024, then plunged by 32.7% to -$31.0 million in 2025, then sank by 96.36% to -$60.9 million in 2026.
- Business Quant data shows STOK's Free Cash Flow at -$60.9 million in Q1 2026, -$31.0 million in Q4 2025, and -$30.4 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | -563.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -389.61 Mn |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 437.80 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 292.04 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 477.44 Mn |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Stoke Therapeutics | 1.96 Bn | 1.66 Bn | - | -58.56 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -58.56 Mn |
| Mar 31, 2026 | -60.94 Mn |
| Dec 31, 2025 | -30.69 Mn |
| Sep 30, 2025 | -30.50 Mn |
| Jun 30, 2025 | -25.58 Mn |
| Mar 31, 2025 | 131.68 Mn |
| Dec 31, 2024 | -23.24 Mn |
| Sep 30, 2024 | -21.72 Mn |
| Jun 30, 2024 | -17.52 Mn |
| Mar 31, 2024 | -24.58 Mn |
| Dec 31, 2023 | -20.88 Mn |
| Sep 30, 2023 | -17.65 Mn |
| Jun 30, 2023 | -22.26 Mn |
| Mar 31, 2023 | -21.90 Mn |
| Dec 31, 2022 | -22.78 Mn |
| Sep 30, 2022 | -24.09 Mn |
| Jun 30, 2022 | -20.61 Mn |
| Mar 31, 2022 | 31.65 Mn |
| Dec 31, 2021 | -16.53 Mn |
| Sep 30, 2021 | -14.96 Mn |